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Summary
Objective: To understand the molecular mechanisms that lead to increased MMP-13 expression and cartilage degeneration during the
progression of osteoarthritis (OA), we have investigated the expression of the transcription factor RUNX2 in OA cartilage and the regulation of
MMP-13 expression by RUNX2 and FGF2 in articular chondrocytes.
Design: RUNX2 and MMP-13 expression in human OA and control cartilage was analyzed by immunohistochemistry. The effects of RUNX2
over-expression, with or without FGF2 treatment, on MMP-13 promoter activity and enzyme accumulation were measured in articular
chondrocytes. Inhibitors of MEK/ERK were assayed for their ability to block FGF2 and RUNX2 up-regulation of the MMP-13 promoter. We
analyzed RUNX2 phosphorylation in response to FGF2.
Results: Fibrillated OA cartilage exhibited increased RUNX2 immunoreactivity when compared to control cartilage. RUNX2 co-localized with
MMP-13 in clusters of chondrocytes in ﬁbrillated OA cartilage. RUNX2 over-expression in cultured chondrocytes increased their
responsiveness to FGF2 treatment, which led to increased MMP-13 expression. Inhibitors of MEK/ERK signaling blocked up-regulation of the
MMP-13 promoter by RUNX2 and FGF2, and also blocked the activation of RUNX2 by FGF2. FGF2 treatment of articular chondrocytes
increased RUNX2 phosphorylation approximately 2-fold.
Conclusions: Increased expression of RUNX2 in OA cartilage may contribute to increased expression of MMP-13. FGF2, which is present in
OA synovial ﬂuid, activated RUNX2 via the MEK/ERK pathway and increased MMP-13 expression. However, it is unlikely that RUNX2 is
a substrate of ERK1/2. RUNX2 expression and activation may be a signiﬁcant step in the progression of OA by promoting changes in gene
expression and chondrocyte differentiation.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Qualitative and quantitative changes in chondrocyte gene
expression contribute to the onset and progression of
osteoarthritis (OA). Understanding the molecular mecha-
nisms that regulate these alterations may lead to strategies
for preventing or arresting progression of this disease.
Collagenases and aggrecanases, secreted by chondro-
cytes, promote degradation of the cartilage extracellular
matrix1e3. Several lines of evidence suggest that matrix
metalloproteinase 13 (MMP-13, also called collagenase 3)
contributes to OA cartilage degradation. The expression
level of MMP-13 is signiﬁcantly higher in the chondrocytes
of late stage OA cartilage when compared to early OA or
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Received 3 February 2003; revision accepted 18 August 2004.96normal knee cartilage4. The release of collagen degradation
products from human OA cartilage is reduced in explant
cultures treated with a speciﬁc inhibitor of MMP-135.
Furthermore, transgenic mice over-expressing activated
MMP-13 in their articular chondrocytes develop joint
degeneration similar to human OA6. Therefore, character-
izing the regulation of MMP-13 expression in articular
chondrocytes will contribute to an understanding of the
molecular etiology of OA.
MMP-13 is also expressed in chondrocytes and osteo-
blasts in the developing skeleton during the process of
endochondral ossiﬁcation7e10. Expression of MMP-13
during development is regulated in part by the transcription
factor RUNX2 (Cbfa1) and MMP-13 expression is di-
minished in RUNX2 null mutant mice11e13. RUNX2 is
a member of a family of transcription factors that contain
a conserved DNA binding domain with homology to the
Drosophila runt gene. RUNX2 function in skeletal de-
velopment is dependent on its binding to the protein Cbfb,
which stabilizes the interaction of RUNX2 with DNA14e16.
The DNA sequence for RUNX2 binding has originally
been described as osteoblast-speciﬁc element 2 (OSE2),
which is essential for expression of the osteoblast-speciﬁc3
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quence of AACCACA. The proximal promoter of the MMP-
13 gene contains one OSE2 site conserved among species
such as human, rabbit, mouse and rat12,19e21. This OSE2
site is located approximately 130 bp 5# of the transcription
starting site in the MMP-13 promoter. RUNX2 binding to the
OSE2 site in the MMP-13 promoter increases transcription
of the gene in cooperation with c-Fos and c-Jun binding to
a neighboring AP-1 site13,20e23. The expression of MMP-13
is up-regulated by several growth factors and cytokines
through activation of RUNX2. In osteoblasts and osteosar-
coma cells, the induction of MMP-13 expression by para-
thyroid hormone (PTH) is dependent on RUNX2 and
AP-113,20,24. IL-1 is a potent stimulator of MMP-13 expres-
sion in chondrocytes, and its effects are diminished in cells
expressing a dominant-negative mutant of RUNX23,21.
FGF2 also stimulates MMP-13 expression in osteoblasts,
chondrosarcoma cells and articular chondrocytes25e27.
FGF2 binds to heparan sulfate proteoglycans in the
extracellular matrix. Studies have shown that FGF2 is
released from the matrix upon damage to the cartilage, and
the released FGF2 stimulates MAPK signaling and MMP
expression, which may initiate tissue remodeling28. Fur-
thermore, FGF2 accumulates in the synovial ﬂuid of OA
joints29, which suggests that FGF2 could contribute to the
progression of OA through up-regulation of MMPs. FGF
signaling up-regulates RUNX2 expression and activity in
osteoblasts30,31. However, the effects of this growth factor
on RUNX2 activity in articular chondrocytes have not been
investigated. It is also unclear whether up-regulation of
MMP-13 by FGF2 in articular chondrocytes is mediated
through the regulation of RUNX2 activity.
In order to advance our understanding of pathways
regulating MMP-13 expression in degenerative joint dis-
eases, we have examined the expression of RUNX2 in
human OA cartilage and the involvement of FGF2 signaling
in the regulation of RUNX2 activity and MMP-13 expression
in articular chondrocytes. We further analyzed the mecha-
nisms by which FGF2 regulates RUNX2 activity and the
expression of MMP-13. Our ﬁndings support the hypothesis
that increased MMP-13 expression in OA cartilage is due
in part to increased RUNX2 expression and the activation




Joint specimens were obtained with informed consent
from patients undergoing knee or hip replacement under
Institutional Review Board approval, George Washington
University, Washington, DC. Specimens were stored at 4(C
and cartilage tissue was dissected from the underlying bone
within 24 h. For histology, small blocks, approximately
3 mm on each side were mounted in OCT compound
(Sakura Finetek USA, Inc. Torrance, CA) and snap frozen
in liquid nitrogen. OA specimens exhibited regions of
macroscopic roughness, ﬁssuring and in some cases
eburnation. These specimens were referred to as ‘‘severe
OA’’. Other regions from the same joint exhibited no
macroscopic roughness, but mild ﬁbrillation was observed
at a microscopic level. These specimens were referred to
as ‘‘mild OA’’. Specimens from patients with no history
of joint disease, undergoing hip replacement as a result
of fracture, exhibited no macroscopic or microscopicroughness or ﬁbrillation. These specimens were referred
to as ‘‘control’’. Bovine articular cartilage from the meta-
carpophalangeal joints of animals 18e22 months of age,
which exhibited no signs of degeneration, was obtained
from a local abattoir (J.W. Treuth & Sons, Baltimore, MD)
within 4 h of slaughter.
CHONDROCYTE ISOLATION AND CULTURE
Human or bovine chondrocytes were isolated from
cartilage shavings by enzymatic digestion. The cartilage
was ﬁrst incubated in 0.1% trypsin in Dulbecco’s Modiﬁed
Eagle Medium with antibiotics and antimycotics (100 U/ml
penicillin, 100 mg/ml streptomycin sulfate, 250 ng/ml am-
photericin B; collectively DMEM) at 37(C for 1 h. After three
washes with DMEM the cartilage was minced and in-
cubated in DMEM with 200 U/ml bacterial collagenase type
2 (Worthington, Lakewood, NJ) at a ratio of 10 ml of
collagenase solution per gram wet weight of cartilage in
a shaker incubator at 37(C for 18 h. The suspension was
then ﬁltered through 40 mm mesh and the cells were
washed three times in DMEM with 10% fetal bovine serum
(FBS). Cells were plated in 10 cm tissue culture dishes at
a concentration of 3! 106 cells/dish. Cells were passaged
in DMEM with 10% FBS and used between passages one
and four.
IMMUNOSTAINING
Cartilage tissue frozen in OCT was sectioned and
immunostained as described previously32. For subcellular
localizations, chondrocytes were grown on coverslips and
immunostained as previously described33. Polyclonal rabbit
anti-RUNX2 antibody (M-70; Santa Cruz Biotechnologies,
Santa Cruz, CA) was used at 1:50 dilution and was found
not to cross-react with the closely related transcription
factor RUNX1 (data not shown). Mouse monoclonal anti-
Cbfb antibody (a gift from Dr. Paul Liu, NHGRI, NIH) was
used as undiluted culture supernatant. Nuclei were counter-
stained with Hoechst 33342 (Molecular Probes, Eugene,
OR) according to the manufacturer’s instructions.
RECOMBINANT RUNX2 ADENOVIRUS AND MMP-13
PROTEIN QUANTIFICATION
Human articular chondrocytes were plated in 24-well
plates at 1! 105 cells per well in DMEM/F12 with 10%
FBS. After overnight incubation, cells were infected with
recombinant RUNX2 adenovirus (a gift from Paul Krebs-
bach, University of Michigan) or null adenovirus (Q-
biogene, Montreal, Canada) in 200 ml per well of serum-
free DMEM/F12 at the titers indicated. After 4 h, 1 ml of
medium with serum was added and the cells were
incubated overnight. The cells were changed to serum-free
medium with or without 25 ng/ml FGF2 (R&D Systems,
Minneapolis, MN) and incubated for 72 h. Medium was
collected, diluted from 1:1 to 1:100 in serum-free DMEM/
F12 and the MMP-13 concentration was measured after
APMA activation using a ﬂuorogenic substrate assay
(Fluorokine-E, R&D Systems) according to the manufac-
turer’s instructions.
TRANSIENT TRANSFECTIONS AND PROMOTER ANALYSIS
Bovine chondrocytes were cultured in 10% FBS DMEM/
F12 medium and plated at a density of 1.2! 105 per well in
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with hyaluronidase (Worthington, Lakewood, NJ) at 4 U/ml
for 6 h. DNA transfection was then performed using
FuGene 6 transfection reagent (Roche Molecular Biochem-
icals, Indianapolis, IN) as described by Madry and Trippel34.
Brieﬂy, 1 mg total DNA was mixed with 4.5 ml FuGene 6 and
added to each well. In co-transfection studies, cells of each
well were transfected with 0.5 mg of a plasmid that
expressed mouse RUNX2 with a FLAG epitope tag (a gift
from Rik Derynck, UCSF) together with either 0.5 mg of
6!OSE2 reporter construct (a 6-mer of AACCACA, the
RUNX2 binding OSE2 site driving ﬁreﬂy luciferase expres-
sion, a gift from Paul Liu, NHGRI, NIH) or 0.5 mg of a 405 bp
MMP-13 promoter reporter construct21 (a gift from Con-
stance Brinckerhoff, Dartmouth University). In addition,
0.01 mg pRL-TK Renilla reporter (Promega Corp. Madison,
WI) was added to each well as a control for transfection
efﬁciency. After 12 h, culture medium was changed to 1%
FBS DMEM/F12. At the same time, cells received treat-
ments for the times indicated. Cells were then washed three
times in PBS and lysed in 1! passive lysis buffer (Promega
Corp.). Luciferase activities were quantiﬁed with Dual-
luciferase reporter assay system (Promega Corp.) in
a Fluoskan Ascent FL instrument (Labsystems, Franklin,
MA) and reported as ratio of ﬁreﬂy luciferase activity to
Renilla luciferase activity.
[32P]-LABELING, IMMUNOPRECIPITATION AND WESTERN
ANALYSIS OF RUNX2
Chondrocytes were transfected with RUNX2-expressing
construct for 12 h and then cultured in serum-free DMEM for
another 24 h. Cells were then labeled with [32P]-orthophos-
phate (Amersham Biosciences, Piscataway, NJ) at 100 mCi/
ml in DMEM without sodium phosphate. After labeling for
2 h, cells were treated with FGF2 for the indicated times.
Cells were washed three times in PBS and lysed in 0.5 ml
lysis buffer containing 150 mM NaCl, 50 mM TriseHCl, pH
7.5, 1% Triton X-100, 5 mM EDTA, 5 mM EGTA, 1 mM
sodium vanadate, 10 mM sodium ﬂuoride, 10 mM pyro-
phosphate, 40 mM nitrophenyl-phosphate, 10 mM leupeptin,
10 mM aprotinin, and 100 mM phenylmethylsulphonyl ﬂuo-
ride. Whole cell lysates were precleared by incubation with
protein A-agarose beads (Stratagene La Jolla, CA) for 2 h.
RUNX2 expressed from plasmid transfection was immuno-
precipitated from the precleared lysates with 10 ml anti-
FLAG antibody beads (Sigma-Aldrich) by incubating over-
night at 4(C followed by repeated pelleting and washing of
the beads with lysis buffer.
Immunoprecipitates were subjected to Western analysis
for RUNX2 protein. Brieﬂy, RUNX2 immunoprecipitate was
resolved on SDS 10% polyacrylamide gels followed by
transfer onto polyvinylidene ﬂuoride (PVDF) membranes
(Amersham Biosciences). Membranes were blocked over-
night at 4(C with 5% non-fat dry milk in TBST buffer (10 mM
TriseHCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) and then
probed with the primary antibody at room temperature. A
polyclonal antibody at 2.5 mg/ml (AML3(Ab-1), Oncogene
Research Products, San Diego, CA) was used as the
primary antibody for RUNX2 protein detection. The bound
primary antibody was then visualized with alkaline phos-
phatase-conjugated secondary antibody and an ECF
Western blotting kit (Amersham Biosciences, Piscataway,
NJ) according to the manufacture’s protocol. After
Western analysis, the PVDF membrane was exposed to
a storage phosphor screen (Molecular Dynamics) for 72 h,and [32P]-activity was quantiﬁed on Typhoon 8600 phos-
phoimager (Molecular Dynamics).
QUANTIFICATION OF MRNA EXPRESSION
Total RNA was extracted from cultured cells using
an RNeasy kit (Qiagen Inc. Valencia, CA), and
analyzed by real-time RT-PCR with SYBR green
detection using the iCycler (Bio-Rad, Hercules, CA).




TCA-3#, and 5#-ACCACTGTCCACGCCATCAC-3# and 5#-
TCCACCACCCTGTTGCTGTA-3#, respectively. Expres-
sion of MMP-13 and RUNX2 was normalized as a function
of GAPDH expression.
STATISTICAL ANALYSIS
Numerical data were analyzed by computer software
package for statistical analysis (Excel 2001, Microsoft Co.,
Redmond, WA). Statistical signiﬁcance was determined
using Student’s t-test using a conﬁdence level of 95%
(P! 0.05).
Results
RUNX2 EXPRESSION IN OA CARTILAGE
In order to investigate possible associations between
RUNX2 and MMP-13 in OA cartilage, we localized RUNX2
and MMP-13 in OA and aged control cartilage using
immunohistochemistry (Fig. 1). In adjacent sections,
RUNX2 and MMP-13 were widely detected in OA cartilage,
with nearly all cells within chondrocyte clusters staining for
both proteins [Fig. 1(B and D)]. In contrast, RUNX2 was
rarely observed in articular surface or mid-zone chondro-
cytes in the control cartilage [Figs. 1(A) and 2(A)]. However,
RUNX2 was frequently detected in the deep zone of control
healthy cartilage. MMP-13 immunostaining of control hip
cartilage revealed cellular staining in a few, randomly
distributed chondrocytes [Fig. 1(C)]. In OA cartilage, the
degree of articular cartilage ﬁbrillation correlates with the
extent of progression of this disease. We further character-
ized a correlation between the degree of cartilage ﬁbrillation
and the percentage of RUNX2 positive cells by staining for
RUNX2 expression in sections from severely ﬁbrillated OA
cartilage, minimally ﬁbrillated OA cartilage and control, non-
ﬁbrillated OA cartilage [Fig. 2(C)]. Chondrocytes in these
sections were assigned to the deep zone (within 275 mm
from the osteo-chondral junction), the middle zone
(275e550 mm) and the superﬁcial zone (greater than
550 mm from subchondral bone). The percentage of RUNX2
positive chondrocytes in the deep zone was not statistically
different between OA and control cartilage. However, in the
middle zone, severely ﬁbrillated OA cartilage had a signif-
icantly higher percentage of RUNX2 positive chondrocytes
(76% vs 29%, p! 0.05). In the superﬁcial zone, the
percentage of RUNX2 positive cells was higher in sections
of minimally ﬁbrillated OA cartilage when compared to
control (44% vs 1.5%, p! 0.05). The superﬁcial zone was
eroded in the severely ﬁbrillated OA specimens, precluding
analysis. An overall analysis of RUNX2 staining of
chondrocytes of all zones demonstrated the highest
percentage in severely ﬁbrillated OA specimens (76%) vs
966 X. Wang et al.: RUNX2 function in osteoarthritisFig. 1. Co-localization of RUNX2 and MMP-13 in clusters of chondrocytes in osteoarthritic (OA) cartilage. Adjacent sections from an OA lesion
(B,D) from the femoral head of a 47-year-old male, and adjacent sections of control cartilage (A,C) from the femoral head of an 78-year-old
female were stained with antibodies to RUNX2 (A,B) or MMP-13 (C,D). The immuno-reactive product is dark brown and the sections were
counterstained with haematoxylin rendering the nuclei purple. BarZ 100 mm.
Fig. 2. Increased expression of RUNX2 in OA cartilage. Articular cartilage was cut from the subchondral bone and full thickness sections were
immunostained for RUNX2 and counterstained for nuclei (haematoxylin). Zones of the sections were assigned as the deep zone (within
275 mm of subchondral bone), the middle zone (between 275 and 550 mm) and the superﬁcial zone (greater than 550 mm from bone) using
a calibrated reticle. (A and B) The middle zone from the femoral head of 83-year-old female control (A) shows only a few RUNX2-expressing
chondrocytes while the middle zone from the femoral head of a 38-year-old female OA patient (B) shows a majority of RUNX2 positive
chondrocytes. BarZ 20 mm. (C) Sections from OA patients were sub-categorized as severe OA or mild OA (for deﬁnitions, see Materials and
methods) and the percentage of RUNX2-expressing chondrocytes in each zone were counted. The graph represents the combined data from
ﬁve OA patients and three controls with at least three sections from each patient examined. Data represent meanG standard deviation (SD).
*P! 0.05 when compared with the control of the same zone.
967Osteoarthritis and Cartilage Vol. 12, No. 12control cartilage (32%, p! 0.01), and less eroded OA
cartilage was intermediate to these (57%).
Articular chondrocytes in culture obtained from eroded
OA cartilage on the femoral condyles of a 70-year-old
female exhibited nuclear RUNX2 immunostaining in ap-
proximately 35% of the cells [Fig. 3(B)]. In these cells,
RUNX2 was co-localized in the nucleus with Cbfb, an
essential binding partner of RUNX proteins [Fig. 3(C)].
CBFb exhibited a nuclear localization in all of the cells,
including those in which RUNX2 was not detectable.
RUNX2 AND FGF2 REGULATION OF MMP-13 EXPRESSION
In order to determine whether increased RUNX2 expres-
sion contributes to increased MMP-13 expression in
chondrocytes, we over-expressed RUNX2 in cultured
human articular chondrocytes and assayed for MMP-13
accumulation in the culture medium.
Chondrocytes obtained from macroscopically healthy
cartilage from the femoral condyles of relatively young
patients (40e50-year-old) exhibited RUNX2 staining in less
than 5% of the cells [Fig. 4(A,B)]. Using an adenoviral
vector to express RUNX2, we ﬁrst examined the percent-
age of these chondrocytes expressing RUNX2 after
infections with a series of dilutions of the viral preparation.
With an infection of 4! 103 pfu/cell, immunoﬂuorescence
revealed nuclear localization of RUNX2 in 20% of the cells
within 48 h [Fig. 4(C,D)]. When the virus dose was
increased to 2! 104 pfu/cell, 60% of the cells showed
positive staining for RUNX2 and no changes in cell
morphology were found [Fig. 4(E,F)]. Infection of cells with
a control vector adenovirus at any doses did not affect
RUNX2 staining (not shown).
The isolated human chondrocytes expressed low levels
of MMP-13 when cultured in serum-free medium [Fig. 4(G)].
Infecting the chondrocytes with RUNX2 adenovirus or
a control vector adenovirus at 2! 103 or 2! 104 pfu/cell
did not signiﬁcantly affect the concentration of MMP-13 in
the culture medium during three days of incubation.
Since RUNX2, like other transcription factors, may
require post-translational activation, we next determined
whether the addition of FGF2 to the serum-free medium
would affect MMP-13 expression with or without RUNX2
over-expression. Treatment of human articular chondrocyte
cultures with a single dose of FGF2 at 25 ng/ml caused an
increase in the concentration of MMP-13 in the culturemedium within three days [Fig. 4(G)]. RUNX2 over-
expression further elevated the responsiveness of these
chondrocytes to FGF2. When human articular chondrocytes
were infected with the RUNX2 adenovirus at 2! 103 pfu/
cell and then treated with FGF2, the MMP-13 concentration
in the medium was 150% higher than that of cultures treated
with FGF2 alone (P! 0.05). A higher dose of the RUNX2
adenovirus at 2! 104 pfu/cell increased MMP-13 secretion
330% higher upon FGF2 treatment. The control vector
adenovirus did not change FGF2 effects on MMP-13
secretion [Fig. 4(G)].
In order to determine whether FGF2 treatment affected
MMP-13 or RUNX2 mRNA levels, we quantiﬁed message
levels using real-time RT-PCR normalizing for GAPDH.
FGF2 up-regulated the level of MMP-13 mRNA in bovine
articular chondrocytes within 24 h of treatment and this
effect was sustained through the eight-day experimental
period [Fig. 5(A)]. During this time course, there was
a modest increase in RUNX2 expression in the control
cultures whereas RUNX2 expression in FGF2 treated
cultures remained relatively constant [Fig. 5(B)].
The effects of FGF2 treatment and RUNX2 over-
expression on MMP-13 protein and mRNA levels may
result from changes in the MMP-13 promoter activity. In
order to examine this possibility, we investigated the
responsiveness of a 405 bp MMP-13 promoter construct
to FGF2 treatment and RUNX2 over-expression [Fig. 6(A)].
This MMP-13 promoter contains one RUNX2 binding site,
as well as binding sites for other transcription factors
including ETS and AP-120,21. It has been suggested that
RUNX2 constitutively binds to the promoter13,21. Therefore,
in order to determine the extent of RUNX2 activation upon
FGF2 treatment and RUNX2 over-expression, we further
examined the promoter activity of a construct containing
only six tandem repeats of the RUNX binding site
(6!OSE2) [Fig. 6(B)]. Bovine articular chondrocytes
transfected with the MMP-13 promoter construct and
treated with FGF2 at 5, 25 and 100 ng/ml in reduced serum
(2%) medium exhibited an increase in MMP-13 promoter
activity of up to 2-fold [Fig. 6(A)]. FGF4 exhibited a similar
effect (data not shown). Over-expression of RUNX2 with
a plasmid construct increased the MMP-13 promoter
activity by approximately 1.6-fold. However, when chon-
drocytes were co-transfected with the RUNX2-expressing
construct and treated with FGF2 at 25 ng/ml, the MMP-13
reporter activity was increased 4e5-fold [Fig. 6(A,C)].Fig. 3. Nuclear co-localization of RUNX2 with its essential binding partner Cbfb in OA chondrocytes. Chondrocytes were isolated from an OA
lesion of the femoral condyle of a 70-year-old female patient. Nuclei, stained blue, were identiﬁed in the phase contrast image (A). Two color
immunoﬂuorescence was performed using anti-RUNX2 antibodies (B) and antibodies to Cbfb (C). BarZ 50 mm.
968 X. Wang et al.: RUNX2 function in osteoarthritisFig. 4. RUNX2 potentiates the induction of MMP-13 by FGF2.
Chondrocytes were isolated from macroscopically healthy cartilage
from the femoral condyles of OA patients. RUNX2 was over-
expressed in these cultures by infecting cells with a recombinant
RUNX2 adenovirus. (AeF) Human chondrocytes were cultured
without infection (A,B) or infected with RUNX2-expressing adeno-
virus at 4! 103 pfu/ml (C,D) or 2! 104 (E,F). Nuclear staining
(A,C,E) and RUNX2 immunoﬂuorescence (B,D,F) were used to
conﬁrm RUNX2 over-expression. (G) RUNX2 over-expression
signiﬁcantly increased the induction of MMP-13 by FGF2. Cultures
of human chondrocytes infected with the RUNX2 adenovirus at
2! 103 (2 K) or 2! 104 (20 K) pfu/ml or control (Vector)
adenovirus at the same dosage were grown in control medium or
medium with FGF2 (25 ng/ml). After three days, APMA-activated
MMP-13 in the culture medium was quantiﬁed using a ﬂuorogenic
substrate assay. Data represent meanG SD (nZ 3). *P! 0.05
between the two group means as indicated.RUNX2 over-expression and FGF treatment had a similar
effect on the 6!OSE2 reporter activity although the
degree of change was greater with this reporter
[Fig. 6(B)]. FGF2 at 25 ng/ml increased the 6!OSE2
reporter activity in bovine chondrocytes by 176-fold and
RUNX2 over-expression alone increased it by 60-fold.
RUNX2 and FGF2 together up-regulated this reporter by
over 400-fold. These data indicate that the synergistic
effects of FGF2 and RUNX2 on MMP-13 promoter activity
are at least in part due to RUNX2 activation.
MEK/ERK SIGNALING IN RUNX2 ACTIVATION
Previous studies have demonstrated that activation of
RUNX2 by FGF2 requires MEK/ERK signaling in osteo-
blasts30, and protein kinase C (PKC) signaling in osteo-
blasts and osteogenic cell lines31. To test whether the MEK/
ERK pathway and/or PKC is required for FGF2/RUNX2
synergistic up-regulation of the MMP-13 promoter in
articular chondrocytes, we used two structurally different
inhibitors of MEK1/2 (PD98059 and U0126) and a PKC
inhibitor (calphostin C) in our reporter assays. As described
above, RUNX2 co-transfection alone increased the MMP-
13 reporter expression by approximately 2-fold, and RUNX2
with FGF2 at 25 ng/ml increased it by approximately 5-fold.
These effects of FGF2/RUNX2 were blocked by each of
the MEK1/2 inhibitors in a dose-dependent manner when
added to the cultures 1 h prior to FGF2 treatment [Fig. 6(C)].
The MEK1/2 inhibitors PD98059 at 30 mM and U0126 at
1 mM reduced the MMP-13 reporter expression down to the
level exhibited by RUNX2 over-expression alone. Higher
concentrations of PD98059 (100 mM) or U0126 (10 mM)
further reduced MMP-13 reporter expression to approxi-
mately the basal level, completely blocking the effects of
both RUNX2 over-expression and FGF2 treatment. Con-
sistent with the hypothesis that these effects of FGF2/
RUNX2 and MEK1/2 inhibitors on the MMP-13 reporter
activity are mediated by the OSE2 sites of the MMP-13
promoter, these MEK1/2 inhibitors had a similar effect on
the 6!OSE2 reporter in these experiments [Fig. 6(D)]. The
MEK1/2 inhibitors reduced the FGF2/RUNX2 synergistic
effects on the 6!OSE2 reporter activity in a dose-de-
pendent manner. In contrast, FGF2/RUNX2 co-stimulation
of the MMP-13 and 6!OSE2 reporters was not affected by
the general PKC inhibitor calphostin C [Fig. 6(C,D)].
RUNX2 PHOSPHORYLATION
One mechanism through which FGF2 may activate
RUNX2 is by altering its phosphorylation state. We assayed
for FGF2 induced changes in RUNX2 phosphorylation in
bovine articular chondrocytes. 32P-metabolically labeled
RUNX2 was immunoprecipitated from lysates of cells
treated with FGF2-containing or control medium for 5 min,
30 min, 2 h, 4 h, and 8 h. FGF2 treatment did not change
RUNX2 phosphorylation level at 5 min and 30 min (data not
shown). An increase in RUNX2 phosphorylation was
detected after 2 h of FGF2 treatment and a maximum
increase of approximately 2-fold was observed at 4 h
[Fig. 7(A,B)].
COMPARISON OF FGF2 AND IL-1b EFFECTS
ON MMP-13 EXPRESSION
It has been reported that IL-1 also increases MMP-13
expression and requires RUNX2 for this effect21,35. There-
fore, we compared efﬁcacy of FGF2 and IL-1b in stimulating
969Osteoarthritis and Cartilage Vol. 12, No. 12MMP-13 expression in human chondrocytes. IL-1b at 5 ng/
ml was nine times more potent than FGF2 at 25 ng/ml in
stimulating MMP-13 protein secretion into the culture
medium and 14 times more in increasing MMP-13 mRNA
levels. Co-infection of RUNX2-expressing adenovirus at
2! 103 pfu/cell and 2! 104 pfu/cell increased the effects
of IL-1b on MMP-13 protein secretion by 44% and 83%,
respectively. However, unlike FGF2, IL-1b did not activate
RUNX2 in 6!OSE2 reporter analysis when bovine
chondrocytes were treated with IL-1b alone or co-trans-
fected with RUNX2-expressing plasmid (data not shown).
Discussion
The onset and progression of OA is associated with
changes in gene expression of chondrocytes. By immuno-
histochemistry, we detected a higher percentage of
chondrocytes with RUNX2 expression in OA joints when
compared to control joints of comparable age but without
clinical symptoms of OA. This difference was greatest in the
superﬁcial zone, whereas both OA and control cartilage
exhibited RUNX2 positive chondrocytes in the deep zone
adjacent to the subchondral bone. In the clonal clusters of
chondrocytes characteristic of OA cartilage, nearly every
Fig. 5. FGF2 up-regulates MMP-13 but not RUNX2 message levels.
Bovine articular chondrocytes were cultured in medium with or
without FGF2 (25 ng/ml) and total RNA samples were taken at days
1, 3 and 8. MMP-13 (A) and RUNX2 (B) mRNAs from at least three
cultures were quantiﬁed by real-time RT-PCR and normalized
against GAPDH. Data represent meanG SD (nZ 3 or 4).
*P! 0.05 when compared with the control of the same day.cell exhibited strong RUNX2 immunoreactivity, and these
cells also expressed MMP-13. Although we have not
examined RUNX2 expression in young, healthy joint
cartilage, studies from mice suggest that RUNX2 expres-
sion is not normally present in articular chondrocytes of the
middle and superﬁcial zones in adult joints36. RUNX2 in the
deep zone of articular cartilage may be normally present
throughout adulthood, as there was no signiﬁcant difference
in the percentage of positive staining deep zone chondro-
cytes in OA and control samples in our studies. Further-
more, adult mice retain RUNX2 expression in the
prehypertrophic chondrocytes of articular knee and tempo-
romandibular joint cartilage that are located adjacent to the
subchondral bone36.
RUNX2 is an important regulator of chondrocyte differ-
entiation. Over-expression of RUNX2 in the cartilage of
transgenic mice promotes chondrocyte hypertrophic matu-
ration and endochondral ossiﬁcation, while inhibiting or
eliminating RUNX2 activity delays or blocks chondrocyte
hypertrophic maturation11,37e39. Since this transcription
factor functions as a rate-limiting regulator of chondrocyte
maturation, the normal lack of RUNX2 expression in
articular chondrocytes may maintain their state of differen-
tiation by limiting further differentiation. However, age
associated RUNX2 expression may be induced in articular
chondrocytes though mechanisms that are not yet clear.
The relatively high expression level of RUNX2 associated
with advanced OA may activate a program of gene
expression in articular chondrocytes similar to that exhibited
by hypertrophic chondrocytes in the growth plates. Over-
expression of RUNX2 in chondrocytes promotes collagen
type X and alkaline phosphatase expression, and in
ﬁbroblasts it promotes VEGF expression40,41. Collagen
type X, alkaline phosphatase and VEGF expression are all
up-regulated in OA cartilage42e46. Furthermore, changes in
chondrocyte behavior, including matrix remodeling, pro-
liferation and apoptosis, are associated with the progres-
sion of OA, and these behaviors are characteristic of
chondrocyte maturation and hypertrophy in developing
growth plates47e49. As RUNX2 activity is a key determinant
of chondrocyte maturation in the growth plate and exper-
imentally in permanent cartilage, it may be a focal point of
the abnormal signaling mechanisms that promote the
initiation and progression of OA. Further studies will be
necessary to determine the factor(s) that promotes in-
creased RUNX2 expression in OA articular chondrocytes.
Increased RUNX2 expression in articular chondrocytes
may not be sufﬁcient to increase MMP-13 expression
without growth factor activation. Even though RUNX2 co-
transfection up-regulated the MMP-13 reporter in culture
conditions with reduced serum, there was no signiﬁcant
increase in MMP-13 in the serum-free culture medium of
human chondrocytes infected with the recombinant RUNX2
adenovirus. Our results demonstrated that FGF2 signaling
promoted the activation of RUNX2, resulting in increased
MMP-13 promoter activity, message accumulation and
protein synthesis. Vincent et al.28 suggest that there is
a signiﬁcant pool of FGF2 associated with articular cartilage
matrix, and they demonstrate that cartilage injury mobilizes
this pool of FGF2, resulting in ERK activation in chondro-
cytes and increased expression of MMP-1 and MMP-3.
Analysis of the concentration of FGF2 in the synovial ﬂuid of
OA knees reveals a higher level in severely degenerated
joints when compared to that in mildly degenerated
knees29. Taken together, these data suggest that FGF2
likely contributes to RUNX2 activation and increased MMP-
13 expression in OA cartilage.
970 X. Wang et al.: RUNX2 function in osteoarthritisFig. 6. Up-regulation of the MMP-13 promoter by RUNX2 and FGF2 is dependent on MEK/ERK signaling. Bovine articular chondrocytes were
transfected with an MMP-13 promoter-luciferase construct (A,B) or a luciferase reporter driven by six tandem repeats of the RUNX2 binding
site OSE2 (B,D). Cultures were co-transfected with a RUNX2 expression construct and/or treated with FGF2 as indicated. Luciferase activity
was normalized against a control, co-transfected expression standard based on Renilla luciferase activity. Kinase inhibitors were added (C,D)
1 h prior to FGF2 treatment: CalC (Calphostin C, protein kinase C inhibitor) 0.5 mM; PD98059 (MEK/ERK inhibitor) 5, 30 and 100 mM; U0126
(MEK/ERK inhibitor) 0.1, 1.0, 10 mM. Data represent meanG SD (nZ 3). *P! 0.05 when compared with the control (Ctr) in panels A and B
or between the two group means as indicated in panels C and D.Our investigation of the mechanisms for FGF2 activation
of RUNX2 revealed that MEK/ERK signaling is important for
this process. Two structurally different MEK inhibitors that
block ERK1/2 phosphorylation and activation inhibited the
up-regulation of the MMP-13 reporter by FGF2 and RUNX2.
These inhibitors also blocked FGF2 and RUNX2 up-
regulation of the 6!OSE2 reporter. This suggests that
ERK1 and/or ERK2 phosphorylation by MEK was required
for the activation of RUNX2 by FGF2 signaling. When
RUNX2 was activated by FGF2 signaling through the MEK/
ERK pathway, it increased transcription of the MMP-13
gene. However, it is unlikely that RUNX2 is a direct
substrate of ERK1/2 in FGF2 stimulated articular chondro-
cytes. FGF2 treatment of articular chondrocytes led to
increased RUNX2 phosphorylation, but only after 2e4 h oftreatment, even though ERK phosphorylation was detected
after only 5 min of FGF2 treatment (data not shown).
Similarly, Xiao et al.30 have demonstrated ERK phosphor-
ylation within minutes of treating an osteoblast cell line with
FGF2, while RUNX2 phosphorylation does not occur for
several hours. This lag between ERK and RUNX2
phosphorylation suggests that there are multiple steps
between these events that may include activation of other
kinases.
Multiple phosphorylation sites are present on RUNX2
protein50,51. Phosphorylation of RUNX2 at different sites
exhibits either inhibitory or stimulatory effects on RUNX2
activity. Wee et al.51 have shown that RUNX2 is constitu-
tively phosphorylated at S104 and S451 (SWISS-PROT,
Accession no. NP-004339) in cells cultured in DMEM
971Osteoarthritis and Cartilage Vol. 12, No. 12supplemented with 10% FBS. Phosphorylation of RUNX2 at
these sites inhibits RUNX2 activity. On the other hand, in
vitro studies have revealed that protein kinase A (PKA)
phosphorylates RUNX2 at the PKA site in activation
domain-350. This phosphorylation is believed to be re-
sponsible for a PKA-dependent transactivation of RUNX2
induced by PTH, which stimulates MMP-13 promoter
activity. Although FGF2 increases RUNX2 phosphorylation
associated with increased activity of this transcription
factor30,52 (Fig. 7 of this paper), the phosphorylation site
has not been determined. Further studies on RUNX2
phosphorylation will contribute to an understanding of the
mechanisms through which FGF2 and MEK/ERK signaling
regulate the expression of MMP-13 and other RUNX2
dependent genes.
IL-1b induced MMP-13 expression in cultured cells more
potently than FGF2. RUNX2 over-expression enhanced IL-
1b effects on MMP-13 protein secretion. However, RUNX2
was not activated by IL-1b in the 6!OSE2 reporter
analysis. Mengshol et al. have also demonstrated that
IL-1b does not induce transiently transfected MMP-13
promoter, while stably transfected MMP-13 promoter does
respond to IL-1b21. It has been suggested that RUNX2
mediates chromatin remodeling to control gene expression
at transcriptional level53. It is possible that RUNX2 may
regulate gene expression by various mechanisms in the
context of nuclear environment. One mechanism may
involve local changes in the factors bound to the proximal
Fig. 7. FGF2 promotes a modest increase in RUNX2 phosphory-
lation. One of the duplicated experiments is shown. Epitope tagged
RUNX2 was transiently expressed in bovine articular chondrocytes.
The cells were metabolically labeled with 32P-orthophosphate and
treated with FGF2 (25 ng/ml) for 2, 4, or 8 h. After immunoprecip-
itation of the tagged RUNX2, the 32P-labeled and total RUNX2 were
quantiﬁed by phosphorimager analysis and immunoblotting for
RUNX2, respectively (A). The ratio of signal from 32P-labeled and
total RUNX2 in each band was graphed (B).promoter of the target gene. Another may require broader
changes in chromatin structure. RUNX2 may mediate FGF2
and IL-1b effects on MMP-13 expression by these different
mechanisms.
MMP-13 expression contributes to normal cartilage
remodeling during endochondral ossiﬁcation and to abnor-
mal articular cartilage degradation in rheumatoid arthritis
and osteoarthritis. In addition to the structural changes in
cartilage matrix caused by the activity of this enzyme,
evidence suggests that MMP-13 activity contributes to the
regulation of chondrocyte differentiation. Inhibition of MMP-
13 activity in cultures of prehypertrophic chondrocytes
suppresses hypertrophic differentiation as demonstrated
by decreased expression of ColX, Cbfa1 (RUNX2) and
MMP-1354. Although the mechanisms through which MMP-
13 regulates chondrocyte differentiation have not yet been
elucidated, the degradation of cartilage matrix may facilitate
the release of growth and differentiation factors associated
with the matrix and the binding of these factors to their
receptors on the surface of chondrocytes. Signaling by
these matrix-released factors may promote chondrocyte
differentiation and stimulate additional MMP expression by
up-regulating RUNX2 expression and activity. While in-
creased MMP expression in response to cartilage injury
may initially facilitate repair of the damaged tissue,
alterations in the regulation of MMP expression due to
age or the extent of injury may lead to abnormal matrix
degradation and joint degeneration.
In summary, our ﬁndings contribute to an understanding
of the mechanisms that regulate increased MMP-13
expression in OA cartilage. We demonstrated that FGF2
signaling through the MEK/ERK pathway increased
RUNX2 activity, leading to increased MMP-13 promoter
activity and protein accumulation. Consistent with the
results of these experiments in isolated articular chondro-
cytes, we demonstrated co-expression of RUNX2 and
MMP-13 in sections of OA cartilage. Since RUNX2 activity
is a rate-limiting determinant of chondrocyte hypertrophic
differentiation during endochondral ossiﬁcation, increased
RUNX2 activity in articular chondrocytes may contribute to
similar changes in differentiation, leading to the abnormal
gene expression and cartilage degeneration associated
with osteoarthritis.
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